Study of the Safety, Tolerability and Efficacy of NP-101 in Treating High Risk Participants Who Are Covid-19 Positive.

NCT05785390 · clinicaltrials.gov ↗
PHASE2
Phase
TERMINATED
Status
170
Enrollment
INDUSTRY
Sponsor class

Stopped The interim analysis results met protocol and SAP predetermined criteria for stopping early due to futility or efficacy.

Conditions

Interventions

Sponsor

Novatek Pharmaceuticals